• Source: Danuglipron

Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.




See also


Lotiglipron
Orforglipron




References

Kata Kunci Pencarian:

• Danuglipron
• Orforglipron
• Lotiglipron
• Semaglutide
• Tirzepatide
• Retatrutide
• Glucagon-like peptide-1
• Dipeptidyl peptidase-4 inhibitor
• Dapagliflozin
• GLP-1 receptor agonist